Posted by Michael Wonder on 20 Aug 2017
HIV preventative drug subsidy negotiations have stalled
18 August 2017 - Requests for a Truvada Pharmaceutical Benefits Scheme listing have been deferred.
A government body responsible for managing taxpayer-subsidised medications deferred a recommendation for an HIV preventative drug to be listed on the PBS on Friday, citing poor cost-effectiveness and consumer modelling.
The Pharmaceutical Benefits Advisory Committee refused to approve the drug used in HIV pre-exposure prophylaxis (PrEP), Tenofovir (better known by its brand name, Truvada) for the PBS, instead requesting more information from the drug's sponsor and production companies in Australia, Gilead Sciences and Mylan Australia, before moving forward.
